Astrazeneca moves ahead with development of Selumetinib
22nd Oct 2013 07:55
Drugs giant AstraZeneca said Tuesday that it had initiated the third phase of its clinical programme for Selumetinib, a treatment which has been formulated for patients with a particular type of lung cancer. The group said the first patient with advanced (or metastatic) non-small cell lung cancer
Read moreFTSE 100 movers: Hargreaves Lansdown extends yesterday's gains
16th Oct 2013 15:14
Shares of Hargreaves Lansdown were leading gains on the Footsie and may have broken above technical resistance at the 1,044p mark after yesterday reporting record levels of assets under administration (AuA) in the fiscal first quarter. The financial services company reported AuA of £39.3bn in the
Read moreLondon pre-open: Strong start expected on FTSE as US hopes grow
15th Oct 2013 07:35
City sources predict the FTSE 100 will open around 35 points higher than yesterday's close of 6,507.65, tracking US stocks higher after they rallied to finish in positive territory on hopes that lawmakers are closing in on a deal to raise the debt ceiling and avert a default. The deal, which has ye
Read moreAstraZeneca acquires oncology-focused biotech firm
15th Oct 2013 07:01
AstraZeneca's biologics research and development arm, MedImmune, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. The drugs giant said MedImmune has also entered into a collaboration agreement with ADC Therapeutics to jointly
Read moreAstraZeneca boosts oncology pipeline
7th Oct 2013 07:55
AstraZeneca announced Monday that MedImmune, its global biologics research and development arm, completed the acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. The deal was made to boost its oncology pipeline by o
Read moreLondon close: Stocks at one-month low on looming US shutdown
30th Sep 2013 16:36
Stocks were firmly lower on Monday as risk appetite was reduced in the face of a looming partial shutdown of the US government after a weekend of no progress in Washington. Political instability in Italy also dampened the mood today as well as disappointing economic data from China, with falls in t
Read moreAstrazeneca progresses with ovarian cancer drug
30th Sep 2013 14:43
AstraZeneca inched higher on Monday after announcing that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib, a drug used in the maintenance treatment of patients with a particular type of ovarian cancer. The group said olaparib has the pote
Read moreFTSE 100 movers: Miners weigh heavily after Chinese data disappoints
30th Sep 2013 14:19
Mining stocks declining sharply today on the back of the disappointing data from the world's top metals user, China. Fresnillo, Anglo American, Antofagasta, Glencore Xstrata and Rio Tinto were all falling sharply. China´s manufacturing sector purchasing managers´ index (PMI) for the month of Septe
Read moreLondon midday: Miners drag FTSE 100 to one-month low
30th Sep 2013 11:42
Concerns over a potential government shutdown in the US, political chaos in Italy and disappointing economic figures from China sparked steep falls on equity markets across Europe on Monday morning, with the FTSE 100 slipping to levels not seen in a month. The FTSE 100 was trading around 0.85% lowe
Read moreAstraZeneca delivers good news on Naloxegol
27th Sep 2013 07:31
Pharmaceutical giant AstraZeneca said the European Medicines Agency had accepted the marketing authorisation application for its constipation tablet Naloxegol. The investigational drug is aimed at relieving constipation caused by pain-killing opioid medicines. It was developed using technology from
Read moreLondon close: Stocks hit by Bullard comments as post-Fed rally fades
20th Sep 2013 16:39
The exuberant post-Fed mood quickly faded on Friday with comments from one US policymaker dampening stocks before the close of trade. Risk appetite was also scaled back as caution set in ahead of the German elections at the weekend with the outcome still highly uncertain. The FTSE 100 finished 28.
Read moreAstraZeneca flu vaccine wins backing from EU regulators
20th Sep 2013 15:08
Pharmaceuticals group AstraZeneca has received a green light from European regulators for its nasal influenza vaccine, giving its share price a small boost on Friday. The company said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a "posit
Read moreBroker tips: AstraZeneca, Pennon, Wetherspoon
13th Sep 2013 12:57
Jefferies has slashed its price target for pharmaceuticals group AstraZeneca (AZN) from 3,200p to 2,850p on the back of its concerns about the company's position in the respiratory market. The broker, which maintained its 'hold' rating for the stock, said that AZN's respiratory portfolio "does not
Read moreBroker snap: Jefferies cuts AstraZeneca target on respiratory concerns
13th Sep 2013 12:25
Jefferies has slashed its price target for pharmaceuticals group AstraZeneca (AZN) from 3,200p to 2,850p on the back of its concerns about the company's position in the respiratory market. The broker, which maintained its 'hold' rating for the stock, said that AZN's respiratory portfolio "does not
Read moreFriday broker round-up UPDATE
13th Sep 2013 08:26
ASOS: Panmure Gordon raises target price from 4555p to 5950p maintaining a buy recommendation. AstraZeneca: Jefferies reduces target price from 3200p to 2850p and retains a hold recommendation. Barclays: Jefferies initiates with a target price of 367p and a buy recommendation. Barratt Development
Read more